Sökning: "Genetic disposition"
Visar resultat 6 - 10 av 23 avhandlingar innehållade orden Genetic disposition.
6. In vitro and in silico prediction of drug-drug interactions with transport proteins
Sammanfattning : Drug transport across cells and cell membranes in the human body is crucial for the pharmacological effect of drugs. Active transport governed by transport proteins plays an important role in this process. A vast number of transport proteins with a wide tissue distribution have been identified during the last 15 years. LÄS MER
7. Interindividual differences in xenobiotic-metabolising enzymes : the human genetic factor
Sammanfattning : The vast number of human xenobiotic-metabolising enzymes display interindividual variability that can alter the disposition of any compound metabolised by these enzymes, including environmental chemicals and many clinically used drugs. Both genetic and non-genetic factors affect the levels and activities of these enzymes. LÄS MER
8. Pathogenesis of type 2 diabetes -role of defects in insulin secretion and insulin sensitivity
Sammanfattning : Type 2 diabetes is characterised by defects in insulin sensitivity, insulin secretion and increased endogenous glucose production. The relative contribution of each of these defects remains controversial. LÄS MER
9. In vivo Pharmacokinetics of Two New Thrombin Inhibitor Prodrugs : Emphasis on Intestinal and Hepatobiliary Disposition and the Influence of Interacting Drugs
Sammanfattning : Biliary excretion is an important elimination route for many drugs and metabolites. For such compounds, it is important to know the extent of excretion and drug exposure in the bile, e.g., for the risk assessment of drug interactions, liver toxicity and the effects of genetic variants. LÄS MER
10. Studies of drug disposition in hemodialysis patients : impact of genetics, inflammation and vitamin D
Sammanfattning : Chronic kidney disease (CKD) patients are at a high risk for drug adverse effects due to accumulation of drugs, which normally are excreted via the kidneys. It is believed that drugs that are metabolized by the liver are safe to prescribe in normal doses to end-stage renal disease (ESRD) patients. LÄS MER